GH Research PLC (NASDAQ:GHRS) — Market Cap & Net Worth
Market Cap & Net Worth: GH Research PLC (GHRS)
GH Research PLC (NASDAQ:GHRS) has a market capitalization of $1.97 Billion ($1.97 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6249 globally and #1994 in its home market, demonstrating a 4.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GH Research PLC's stock price $28.72 by its total outstanding shares 68642287 (68.64 Million). Also see balance sheet size of GH Research PLC for a full breakdown of the balance sheet.
GH Research PLC Market Cap History: 2021 to 2026
GH Research PLC's market capitalization history from 2021 to 2026. Data shows growth from $1.60 Billion to $1.97 Billion (7.95% CAGR). Also see GH Research PLC operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
GH Research PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.07% | #176 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #714 of 3165 |
Weight: GH Research PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GH Research PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GH Research PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GHRS share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GHRS by Market Capitalization
Companies near GH Research PLC in the global market cap rankings as of September 18, 2026. Review GHRS tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GH Research PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
GH Research PLC Historical Marketcap From 2021 to 2026
Between 2021 and today, GH Research PLC's market cap moved from $1.60 Billion to $ 1.97 Billion, with a yearly change of 7.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.97 Billion | +126.14% |
| 2025 | $871.76 Million | +81.43% |
| 2024 | $480.50 Million | +20.69% |
| 2023 | $398.13 Million | -40.33% |
| 2022 | $667.20 Million | -58.34% |
| 2021 | $1.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of GH Research PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.97 Billion USD |
| MoneyControl | $1.97 Billion USD |
| MarketWatch | $1.97 Billion USD |
| marketcap.company | $1.97 Billion USD |
| Reuters | $1.97 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more